Evidence map›Paper›PMID 36650023›Full record

ArticleJournal for immunotherapy of cancer2023

Novel combination strategy of high intensity focused ultrasound (HIFU) and checkpoint blockade boosted by bioinspired and oxygen-supplied nanoprobe for multimodal imaging-guided cancer therapy.

Rui Tang, Hongye He, Xiaohong Lin, Nianhong Wu, Li Wan, Qiaoqi Chen, Yaqin Hu, Chen Cheng, Yuting Cao, Xun Guo and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 2 pooled it
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. HIFU-Driven Targeted Pyroptosis Therapy in Basal-Like Breast Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Rui Tang *Department of Ultrasound, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Hongye He *Department of Ultrasound, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Xiaohong Lin *Institute of Ultrasound Imaging of Chongqing Medical University, Chongqing, China.
Nianhong WuDepartment of Ultrasound, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Li WanDepartment of Ultrasound, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Qiaoqi ChenDepartment of Ultrasound, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Yaqin HuDepartment of Ultrasound, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Chen ChengDepartment of Ultrasound, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Yuting CaoDepartment of Ultrasound, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Xun GuoDepartment of Ultrasound, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Ying ZhouDepartment of Ultrasound, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Xialin XiongDepartment of Ultrasound, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Min ZhengDepartment of Ultrasound, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Qi WangState Key Laboratory of Ultrasound in Medicine and Engineering, College of Biomedical Engineering, Chongqing Medical University, Chongqing, China.
Faqi LiState Key Laboratory of Ultrasound in Medicine and Engineering, College of Biomedical Engineering, Chongqing Medical University, Chongqing, China.
Yang ZhouDepartment of ultrasound, The Third People's Hospital of Chengdu City, Chengdu, People's Republic of China.
Pan LiDepartment of Ultrasound, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China lipan@hospital.cqmu.edu.cn.ORCID 0000-0002-0316-0355
Dalian Medical University · CNChongqing Medical University · CNFirst People's Hospital of Chongqing · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHigh-intensity focused ultrasound (HIFU) has shown considerable promise in treating solid tumors, but its ultrasonic energy is easily attenuated, resulting in insufficient energy accumulation in the target area. Moreover, HIFU ablation alone may inevitably lead to the presence of residual tumors, which may cause tumor recurrence and metastasis. Here, we describe a synergistic regimen combining HIFU facilitation with immunomodulation based on a novel oxygen-carrying biomimetic perfluorocarbon nanoparticle (M@P-SOP) to stimulate immunogenic cell death in tumor cells while alleviating immune suppression tumor microenvironment.

methodsM@P-SOP was prepared by double emulsion and film extrusion method. The anticancer and antimetastatic effects of M@P-SOP were evaluated on a preclinical transplanted 4T1 tumor model by combining HIFU and immunotherapy. Flow cytometry and immunofluorescence were used to clarify the potential mechanism of HIFU+M@P-SOP and their role in anti-programmed death ligand-1 (PD-L1) therapy.

resultsGuided by photoacoustic/MR/ultrasound (US) multimodal imaging, M@P-SOP was abundantly enriched in tumor, which greatly enhanced HIFU's killing of tumor tissue in situ, induced stronger tumor immunogenic cell death, stimulated dendritic cell maturation and activated CD8

conclusionsOur findings offer a highly promising HIFU synergist for effectively ameliorating acoustic and hypoxia environment, eventually inhibiting tumor growth and metastasis by stimulating host's antitumor immunity under HIFU ablation, especially in synergizing with PD-L1 antibody immunotherapy.

Indexed as

CD8-Positive T-LymphocytesExtracorporeal Shockwave TherapyNeoplasm Recurrence, LocalNeoplasmsHumansMultimodal ImagingOxygenTumor MicroenvironmentUltrasonographyOxygenimmunotherapytumor microenvironment

Identifiers

PMID36650023
PMCPMC9853265
OpenAlexW4317207492

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.